Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.

@article{Paulsen2017AssessingPA,
  title={Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.},
  author={Erna-Elise Paulsen and Thomas Karsten Kilvaer and Mehrdad Rakaee Khanehkenari and Samer Al-Saad and Sigurd M. Hald and Sigve Andersen and Elin Richardsen and Nora Ness and L T Busund and Roy Martin Bremnes and Tom Donnem},
  journal={Clinical lung cancer},
  year={2017},
  volume={18 2},
  pages={220-233.e8}
}
INTRODUCTION Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand, PD-L1, have gained momentum in the treatment of non-small cell lung cancer (NSCLC). However, their prognostic significance remains controversial. The present study evaluated the expression of PD-L1 and PD-1 and their potential role in an Immunoscore, supplementing the TNM classification of NSCLC. MATERIALS AND METHODS Tissue microarrays constructed from tumor tissue samples from 2 cohorts… CONTINUE READING
Highly Cited
This paper has 19 citations. REVIEW CITATIONS